Open AccessAtazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen
Author(s) -
Esteban Ribera,
Carlos Azuaje,
Rosa María López,
M. Medina Díaz,
María Luisa Velloso Feijoó,
Leonor Pou,
Manuel Crespo,
Adrián Curran,
Imma Ocaña,
Albert Pahissa
Publication year - 2006
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/01.aids.0000226953.56976.ad
Subject(s) - cmin , lopinavir , atazanavir , ritonavir , pharmacokinetics , cmax , saquinavir , medicine , regimen , pharmacology , tolerability , lopinavir/ritonavir , adverse effect , viral load , human immunodeficiency virus (hiv) , virology , antiretroviral therapy
To assess the pharmacokinetics and tolerability of lopinavir (LPV), ritonavir (RTV) and atazanavir (ATV) as a double-boosted protease inhibitor regimen in HIV-infected adults.